An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
NCT ID: NCT02161159
Last Updated: 2016-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
515 participants
OBSERVATIONAL
2014-06-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
NCT02673047
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
NCT00915525
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
NCT01852058
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
NCT03320850
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
NCT02590250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients With Urinary Incontinence Due to iOAB
Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
botulinum toxin Type A
botulinum toxin Type A administered in accordance with physician standard practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
botulinum toxin Type A
botulinum toxin Type A administered in accordance with physician standard practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
David Brix
Bad Mergentheim, , Germany
Urologie Turmschtraße
Berlin, , Germany
Uwe-Carsten
Berlin, , Germany
Albrecht Kastein
Berlin, , Germany
ATURO
Berlin, , Germany
MVZ Burgdorf
Burgdorf, Hanover, , Germany
Ev.-Luth. Diakonissenanstalt Dresden
Dresden, , Germany
Stefan Carl
Emmendingen, , Germany
Zentrum für Urologie FFM
Frankfurt, , Germany
Georg-August-Universität Göttingen
Göttingen, , Germany
Universitätsklinikum Halle (Saale)
Halle, , Germany
Urologikum Hamburg
Hamburg, , Germany
Urologische Praxis Volksdorf
Hamburg, , Germany
Claudia Olszak-Warnat
Herne, , Germany
Westpfalz-Klinikum Kaiserslautern
Kaiserslautern, , Germany
Urologie Zentrum Kiel
Kiel, , Germany
Joachim Weiß
Lampertheim, , Germany
Uro- Vital-Zentrum, GP Hellmeier, Krause et al
Landshut, , Germany
Tom Kempe
Leipzig, , Germany
Institut Dr. Schulze
Markkleeberg, , Germany
Elke Stagge
Mülheim, , Germany
Universitätsklinikum Münster
Münster, , Germany
Urologen am Stadtpark
Nuremberg, , Germany
Urologicum Osnabrück
Osnabrück, , Germany
Simone Maier
Reutlingen, , Germany
Andres Melchior
Salzatal OT Schiepzig, , Germany
Andreas Reinhard Wicht
Sangerhausen, , Germany
Franz Hirschle
Singen, , Germany
Wolfgang Theurer
Stuttgart, , Germany
Benjamin Fischer
Tuttlingen, , Germany
Dietmar Jung
Tuttlingen, , Germany
Kontinenzzentrum Südwest
Villingen-Schwenningen, , Germany
Hospital Universitario Burgos
Burgos, , Spain
Hospital de Cabueñes
Gijón, , Spain
Hospital Virgen de la Victoria
Málaga, , Spain
Complejo Hospitalario Universitario Ourense
Ourense, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital Universitario Salamanca
Salamanca, , Spain
Hospital Universitario Marqués de Valdecilla
Santander, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital de Valme
Seville, , Spain
Urologimottagningen, Hallands Sjukhus Halmstad
Halmstad, , Sweden
Urologiska kliniken, Södersjukhuset AB
Stockholm, , Sweden
Karolinska Hospital
Stockholm, , Sweden
Karolinska Hospital
Stockholm, , Sweden
Kvinnokliniken, Danderyds Sjukhus AB
Stockholm, , Sweden
Kirurgkliniken, Västervik Sjukhus
Västervik/Kalmar, , Sweden
Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Edgbaston
Birmingham, , United Kingdom
Southern General Hospital
Glasgow, Lanarkshire, , United Kingdom
Leeds Teaching Hospitals NHS Trust, St. James's University Hospital
Leeds, West Yorkshire, , United Kingdom
University College London Hospitals NHS foundation Trust
London, , United Kingdom
Imperial College Healthcare NHS Trust, The Bays, St Mary's Hospital
London, , United Kingdom
St Helens & Knowsley Teaching Hospitals NHS Trust, Whiston Hospital
Prescot, Merseyside, , United Kingdom
Salisbury NHS Foundation Trust, Salisbury District Hospital
Salisbury, Wiltshire, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Farrelly E, Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, Yu J, Patel A, Nelson M. One treatment with onabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications. Neurourol Urodyn. 2023 Aug;42(6):1203-1213. doi: 10.1002/nau.25221. Epub 2023 Jun 1.
Poster. Female Pelvic Med Reconstr Surg. 2020 Oct 1;26(10S Suppl 1):S89-S189. doi: 10.1097/SPV.0000000000000936. No abstract available.
Short orals. Female Pelvic Med Reconstr Surg. 2020 Oct 1;26(10S Suppl 1):S21-S77. doi: 10.1097/SPV.0000000000000934. No abstract available.
Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, Boroujerdi A, Patel A, Farrelly E. OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J. 2021 Jan;32(1):65-74. doi: 10.1007/s00192-020-04423-0. Epub 2020 Jul 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAF/AGN/NS/OAB/002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.